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2This past year we celebrated the 50th anniversary of
he publication of the seminal paper by Barnes and
outit, which demonstrated for the ﬁrst time in a mouse
odel the existence of a graft-versus-leukemia effect
ediated by donor cells [1]. The paper from Barnes and
outit represented the ﬁrst seed in the development of
ur ﬁeld. This seed bore its ﬁrst fruits almost 20 years
ater when Dr. Thomas reported the transplant out-
omes of the ﬁrst 100 patients treated in Seattle with
igh-dose chemoradiotherapy and allogeneic transplan-
ation as treatment of refractory leukemia [2].
The concepts of dose intensity as a strategy to
vercome cancer cell resistance, hematopoietic pro-
enitor cell rescue as a tool to deliver supralethal
hemoradiotherapy, and ﬁnally the existence of an
mmune-mediated graft-versus-tumor effect still form
he basis of our ﬁeld today.
Despite the fact that we have witnessed major
dvances in our ﬁeld, outcomes for many patients
emain poor. Thus, continued research into the major
auses of treatment failure such as graft-versus-host
isease (GVHD), regimen-related toxicity, relapse
ost-transplant, and post-transplant immunedeﬁ-
iency should be the main focus of our efforts. How-
ver, as I begin my term as Chairman of the Advisory
oard of the Center for International Blood & Mar-
ow Transplant Research (CIBMTR), other chal-
enges to the future development of our ﬁeld includ-
ng continued research into the areas mentioned
bove can be identiﬁed. These areas should be ad-
ressed as opportunities to move our ﬁeld forward and
mprove the outcomes of the patients we serve. The
ost pressing of these challenges as I see them are:
. Access to Hematopoietic Progenitor Cell Trans-
plantation: despite strong evidence demonstratingthe beneﬁts of allografting and autografting in pa-
tients with a variety of hematologic disorders, the
rates of transplantation for many diseases remains
low. The obvious barriers of donor availability and
patient medical condition are being addressed by
developing alternative donor strategies, and devel-
opment of less toxic conditioning regimens. The
other barriers of access to transplant specialists
such as regional distribution of transplant centers,
referral bias, and insurance coverage will require
concerted efforts from us as transplant specialists
and our professional societies to identify and ad-
dress the potential root causes.
. Displacement of Hematopoietic Progenitor Cell
Transplantation by Alternative Therapies: chronic
myelogenous leukemia has shown us how quickly
hematopoietic progenitor cell transplantation can
be replaced by alternative therapies perceived to be
superior. In the case of imatinib, allograft utiliza-
tion was decreasing even before the drug received
U.S. Food and Drug Administration approval for
frontline therapy of this disease. The results with
imatinib undoubtedly justify the displacement of
allografting from frontline therapy in younger pa-
tients with human leukocyte antigen (HLA)-com-
patible donors to second-line therapy [3]. Notwith-
standing, the applicability of this algorithm to
certain speciﬁc populations is not routinely ad-
dressed (ie, pediatric patients or patients with syn-
geneic donors), in which the risk–beneﬁt ratio of
foregoing allografting until the time of treatment
failure may be totally different. With the approval
of new agents for multiple myeloma, lymphoma,
and myelodysplastic syndromes, many disease ex-
perts are questioning the potential role of au-
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Editorial264tografting and allografting in these disorders. The
role of hematopoietic progenitor transplantation
will need to be reassessed with the emergence of
these new agents, and we as a community should be
helping to design, implement, and analyze through
organizations such as the CIBMTR, the BMT
Clinical Trials Network, and the ASBMT in col-
laboration with other cooperative groups, and dis-
ease-speciﬁc research organizations and advocacy
groups such as the MMRF, the IMF, and the Leu-
kemia and Lymphoma Society, among others.
. Increasing Burden of Reporting and Regulatory
Obligations: with the recent publication of the
Health Resources and Services Administration Re-
quest for Proposals to establish and maintain the
Stem Cell Therapeutic Outcomes Database it is
only a matter of time before mandatory reporting
of all hematopoietic progenitor cell transplants be-
comes the “law of the land.” Although such an
initiative is appropriate, the potential for develop-
ing a large unfunded mandate may result in the
closure of many small- to medium-size transplant
units that will be unable to cope with the added
data management demands.
. Replacement of Trained Personnel: the care of
patients undergoing hematopoietic progenitor cell
transplantation has become increasingly more
complex, as we transplant older patients, use alter-
native stem cell doses, and look into the issues of
graft engineering and cellular therapies. Although
FACT and the ASBMT have developed criteria for
what type of training transplant specialists should
have, no formal training curriculum has been de-
veloped, nor has a certiﬁcation program been ap-
proved. Likewise, we need to deﬁne what the po-
tential needs for hematopoietic progenitor
transplant specialists will be so we can effectively
stimulate, recruit, and train the next generation of
hematopoietic progenitor cell transplantation spe-
cialists.
These challenges should actually be viewed as op-
ortunities for the future. The number of patients
ndergoing autologous and allogeneic transplantation
ontinues to increase, the potential indications prom-
se to expand, and the possibility of improving treat-
ent outcomes by incorporating many of the new
gents being developed is tantalizing. Likewise, pro-
pective evaluation of transplant outcome with man-
atory reporting could potentially improve our abili-ies to demonstrate the superiority of transplant to
ther therapeutic strategies as well as serve as a cata-
yst for the eventual development of hematopoietic
rogenitor cell transplantation as a subspecialty with
peciﬁc credentialing requirement that could serve as
n incentive for physicians in training to pursue this
areer. I am proud to say that the CIBMTR has been,
nd will continue to play a major role in addressing
hese challenges and making them into opportunities.
ome examples of how the CIBMTR is addressing
hese challenges include:
Development of the Health Services Subcommittee
Initiation of a Working Committee for Interna-
tional Studies.
Partnering with the NMDP and EMMES Cor-
poration to become the Data Coordinating Cen-
ter for the BMT-CTN.
Performing the ﬁrst studies looking at center
characteristics and outcomes of performance [4,5]
Harmonizing data reporting forms with the
NMDP.
Thus, I continue to encourage all of the members
f the hematopoietic progenitor cell transplantation
ommunity to actively participate in all activities con-
erning the CIBMTR, from data reporting to study
roposals. Inasmuch as we are participants in these
ctivities, the CIBMTR will represent our needs, and
ogether we can improve the ﬁeld of hematopoietic
rogenitor cell transplantation in the beneﬁt of the
atients we see and serve every day.
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